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Abstract
Introduction
Patients receiving antiretroviral therapy (ART) require routine monitoring to track response
to treatment and assess for treatment failure. This study aims to identify gaps in monitoring
practices in Kenya and Uganda.
Methods
We conducted a systematic retrospective chart review of adults who initiated ART between
2007 and 2012. We assessed the availability of baseline measurements (CD4 count,
weight, and WHO stage) and ongoing CD4 and weight monitoring according to national
guidelines in place at the time. Mixed-effects logistic regression models were used to ana-
lyze facility and patient factors associated with meeting monitoring guidelines.
Results
From 2007 to 2012, at least 88% of patients per year in Uganda had a recorded weight at ini-
tiation, while in Kenya there was a notable increase from 69% to 90%. Patients with a docu-
mented baseline CD4 count increased from 69% to about 80% in both countries. In 2012,
83% and 86% of established patients received the recommended quarterly weight monitor-
ing in Kenya and Uganda, respectively, while semiannual CD4 monitoring was less com-
mon (49% in Kenya and 38% in Uganda). Initiating at a more advancedWHO stage was
associated with a lower odds of baseline CD4 testing. On-site CD4 analysis capacity was
associated with increased odds of CD4 testing at baseline and in the future.
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Discussion
Substantial gaps were noted in ongoing CD4 monitoring of patients on ART. Although
guidelines have since changed, limited laboratory capacity is likely to remain a significant
issue in monitoring patients on ART, with important implications for ensuring quality care.
Introduction
Over the past decade there has been a massive scale-up of antiretroviral therapy (ART) in sub-
Saharan Africa. Between 2003 and 2012, the number of people receiving ART in the region
rose from 100,000 to 7.5 million [1,2]. Kenya and Uganda were among the countries that rap-
idly expanded ART services during this time. In Kenya, the number of patients receiving ART
more than doubled between 2008 and 2013, rising from 237,881 to 656,359 [3]. In Uganda, the
number of people on ART has increased by more than 100,000 per year, from 313,117 in 2011
to 570,486 by late 2013 [4,5]. With more patients on treatment, the need to evaluate patients
for ART eligibility, and monitor patients once on treatment, has also increased.
At the time of ART initiation, proper evaluation can identify severely underweight patients,
as well as those with very low CD4 counts who are at higher risk of poor outcomes and may
require closer clinic and provider follow-up [6,7]. Further, clinical staging and/or CD4 counts
are the primary eligibility criteria for ART initiation among non-pregnant adults in most of
sub-Saharan Africa [8].
Once initiated, monitoring a patient’s response to therapy allows providers to detect potential
adherence problems and treatment failure. It is critical to promptly identify treatment failure, as
switching to a second-line regimen for these patients is essential for reducing mortality risk and
preventing the spread of drug resistance [9–11]. Until recently, guidelines relied heavily on clini-
cal and immunological monitoring, a combination that has been shown to be superior than clini-
cal monitoring alone [12–16]. However, the World Health Organization (WHO), Kenya, and
Uganda have recently recommended viral load monitoring, given its better sensitivity, specificity,
and timeliness in detecting treatment failure [8,17–20]. Nonetheless, clinical and immunological
measures are still recommended in the absence of viral load testing.
Despite the need for risk stratification and ongoing monitoring while on ART, relatively lit-
tle is known about how these guidelines are followed in practice. Laboratory testing in sub-
Saharan Africa has largely been hindered by inadequate infrastructure, equipment, and reagent
shortages, and low availability of skilled laboratory professionals [21,22]. Additionally, moni-
toring requires regular care-seeking by patients with HIV, actions that can be limited by finan-
cial, geographical, and psychosocial factors [23–26].
As Kenya and Uganda pursue new monitoring guidelines that include regular viral load test-
ing, it is important to understand how well prior guidelines were followed and to consider why
they may have fallen short in practice. In this paper, we assess recent CD4 and weight monitor-
ing practices and examine facility- and patient-level characteristics associated with meeting
national monitoring guidelines.
Methods
Study sample
This study used data from a subset of facilities from a larger, multi-country facility-based
project that took place in Kenya and Uganda (Access, Bottlenecks, Costs, and Equity [ABCE]
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project) [27]. Nationally representative facility samples were constructed for Kenya and
Uganda using a two-step, stratified random sampling process detailed elsewhere [28,29]. In
sum, subnational units (districts or counties) were stratified by country-specific characteristics
(e.g., socioeconomic features, access to health care, etc.), and districts or counties were ran-
domly selected from each stratum; urban epicenters (Kampala for Uganda; Nairobi and Mom-
basa for Kenya) were purposely included in addition to randomly selected districts or counties.
Within each randomly selected district or county, facilities were stratified by their govern-
ment-determined level of complexity and then randomly selected until a pre-determined quota
was met for each facility type.
Health facilities that declined study participation or where access to the facility was limited
due to safety, travel distance, or time constraints were replaced with other similar facilities
within the same district by the country team when a suitable replacement facility was identi-
fied. Data collection took place from April to November 2012 in both countries.
At all selected facilities that provided ART services, we conducted a retrospective chart
review of adult patients (18 years and older) who initiated ART 6 to 60 months prior to the sur-
vey date. In addition to patients actively in care, we sought to include the charts of all trans-
ferred, defaulted, and deceased patients. We received electronic medical records for all patients
meeting inclusion criteria at four facilities in Kenya. At the remaining facilities in both coun-
tries, the facility administrator reported the total number of eligible charts, and we sampled up
to 250 charts using an equal-probability procedure. At facilities with less than 250 charts, we
included all charts in our study. Two facilities in Uganda provided electronic records for the
sampled patients, while all other information was extracted from paper charts.
Data collection
Trained research associates interviewed facility administrators to collect information about
facility management, resources, practices, and patient volumes. They then extracted informa-
tion related to patient demographics, initiation characteristics, treatment regimen, outcomes,
full visit history, and all test results (CD4 count, weight, and viral load) from the sampled ART
charts. Research associates also searched each patient’s folder for documentation of weight,
CD4 count, or viral load tests that were not recorded in the standard chart and extracted the
relevant information.
We applied sample weights based on the reported number of adult patients in each facility’s
ART program, such that our reported values are representative of all patients at the sampled
facilities. Analyzes related to initiation were weighted based on the annual number of new initi-
ates, while analyzes for ongoing monitoring used the annual number of enrolled patients. We
linearly extrapolated patient numbers for the 9% of facility-years where these data were not
reported. We also extrapolated patient numbers for all facilities in 2012 as the facility survey
only collected information through 2011.
Describing monitoring practices in relation to minimum guidelines
We examined whether each patient met existing national guidelines for minimummonitoring
at baseline and once they were established on therapy. These guidelines were consistent across
countries and years for our study period (2007–2012) [15,16,30].
At ART initiation, both countries called for a measure of weight, CD4 cell count, and WHO
stage. We determined whether each measurement was recorded at some time between three
months prior to and one month following initiation to account for lags between eligibility test-
ing and actual ART initiation; this approach also accounted for the potential that tests per-
formed at ART initiation could be reviewed and recorded at a subsequent visit.
ART Patient Monitoring in Kenya and Uganda
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After the initiation period (typically defined as the first six months) monitoring guidelines
called for a weight measurement every three months and CD4 measurement every six months,
at minimum [15,16,30]. For each calendar month from 2009 to 2012, we restricted our denom-
inator to patients who were (a) established, meaning they initiated ART at least six months
before the given month, and (b) retained, meaning they were alive and on treatment during the
given month, and not transferred, dead, or defaulted (i.e., no visit for six months and never
returning). A patient met CD4 testing guidelines for a given month if a CD4 test was recorded
at any point in the prior six months. Likewise, they met weight guidelines if a weight measure
was recorded in the prior three months. If a patient did not have a test recorded during a speci-
fied time period, we determined whether the patient visited the facility during that period with-
out receiving a test. Results for a given facility type-country-month are only shown if at least 50
charts were included in the calculation.
Determinants of baseline and routine monitoring
We used a series of mixed-effects logistic regressions to assess factors associated with meeting
minimum guidelines. For each country, models were run at the patient level using facility ran-
dom effects.
Two separate analyzes were performed. The first examined determinants of having a base-
line CD4 test and weight measurement, run as separate models, among patients who initiated
therapy between 2011 and 2012. This group, the mostly recently initiating patients in our sam-
ple, was selected because determinants of testing may have changed over time and more
recently measured factors are most relevant to policy and practice.
The second set of analyzes examined the extent to which established patients were meeting
monitoring guidelines at the time of the survey. Patients were included in this analysis if (1)
they were alive and in care at the time of the survey rather than transferred, dead, or defaulted;
and (2) they had initiated at least 12 months prior to the survey, to ensure results were not
influenced by elevated testing in the period immediately following initiation. Separate models
examined two binary dependent variables: (1) CD4 test recorded during the six months prior
to record extraction; and (2) weight recorded in the three months prior to record extraction.
Independent variables were selected a priori based on potential theoretical relationships
with monitoring practices. All models included patient-level characteristics (age and sex), as
well facility-level indicators including facility type (hospital or health center); ownership (pub-
lic or private); age of ART program; on-site CD4 analysis capacity; receipt of HIV-specific staff
training during the past year; and whether nurses led patient treatment.
Models assessing baseline CD4 and weight measurements included an indicator of baseline
disease severity as categorized by four WHO stages.
Models examining recent measurements for established patients included duration on ART
and binary indicators capturing whether the patient showed signs of WHO-defined immuno-
logical or clinical failure in the six months preceding the testing window of interest. Per WHO
definitions [8], potential immunological failure was defined as having a CD4 count lower than
100 or experiencing a CD4 count falling to baselines levels. Potential clinical failure was defined
as experiencing weight loss exceeding 10% from the patient’s highest weight. Other clinical cri-
teria could not be included due to inconsistent recordkeeping.
All analyzes were conducted in Stata 13.1 (Stata Corp., College Station, Texas, USA).
Ethical considerations
Ethical approval for this study was obtained from the University of Washington Human Sub-
jects Division and local institutional review boards in Kenya (Kenya Medical Research Institute
ART Patient Monitoring in Kenya and Uganda
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Ethics Review Committee) and Uganda (Makerere University School of Medicine Research
Ethics Committee). Patient consent for review of clinical charts was not obtained, as all infor-
mation extracted from clinical charts was anonymized and de-identified prior to analysis.
Results
Data from 23,618 patient charts were extracted from 97 facilities offering ART (15,671 charts
from 51 facilities in Kenya and 7,947 charts from 46 facilities in Uganda). Table 1 provides an
overview of sampled facility and patient characteristics.
Facility characteristics
The sampled facilities were largely publicly-owned (79%) and urban (67%). Most facilities had
HIV guidelines available (97%), but only 26% had staff with HIV-specific training during the
previous year. Ugandan facilities in our sample (80%) were more likely to have on-site CD4
analysis capacity than those in Kenya (29%). Most facilities without CD4 analysis capacity took
samples on-site and shipped them elsewhere for analysis; only 3% did not offer any CD4 test-
ing. One hospital each in Uganda and Kenya reported capacity to run viral load assays. Func-
tional adult weight measurement scales (99%) and measuring tapes (92%) were nearly
universally available.
Patient characteristics
The majority of patients were female (64%) with a median age of 36 at initiation. When
recorded, the median baseline CD4 count was 175 and 41% of patients were classified as WHO
stage 3 or 4. Over half of patients initiated in 2010 or 2011.
Baseline monitoring
Between 2007 and 2012, at least 88% of patients had a WHO stage recorded at initiation across
country-years (Fig 1). Weight was recorded for over 94% of patients from all initiating cohorts
in Uganda, while the percentage of Kenyan patients with a baseline weight measurement
increased from 69% in 2007 to 90% in 2012. Baseline CD4 testing rates also increased between
2007 and 2012, rising from 69% to 80% in Uganda and from 69% to 81% in Kenya. Less than
1% of patients received a baseline viral load measure.
Monitoring of established patients
In 2012, 83% and 86% of established patients met the recommended quarterly weight monitor-
ing in Kenya and Uganda, respectively (Fig 2). This was an improvement from 2009, when
76% of Kenyan and 72% of Ugandan patients met weight-monitoring guidelines. Trends in
weight monitoring were either stable or showed improvement across facility types in both
countries. In particular, 85% of patients at rural health centers in Uganda met weight monitor-
ing guidelines in 2012, compared to 49% in 2009. By 2012, all types of facilities in both coun-
tries had at least 80% of established ART patients receiving the recommended weight
measures. These gains occurred in parallel with increases in ART visit frequency, with the pro-
portion of patients with a facility visit every three months increasing from 81% in 2009 to 90%
in 2012.
In 2012, 49% and 38% of established ART patients met the guideline for semi-annual CD4
tests in Kenya and Uganda, respectively (Fig 3). This finding reflects minimal changes in CD4
testing rates since 2009 (43% in Kenya and 35% in Uganda). Rural health centers in Uganda
had the lowest proportion of established patients who received semi-annual CD4 tests over
ART Patient Monitoring in Kenya and Uganda
PLOSONE | DOI:10.1371/journal.pone.0135653 August 14, 2015 5 / 15
Table 1. Characteristics of sampled facilities and patients at initiation.
Indicator Kenya Uganda Total
Facility characteristics
Total number of facilities 51 46 97
Median program start year 2006 2005 2005
Level of complexity
Hospital 53% 59% 56%
Health center 47% 41% 44%
Facility ownership
Government or NGO 90% 67% 79%
Private 10% 33% 21%
Location
Urban or peri-urban 71% 63% 67%
Rural 29% 37% 33%
Monitoring capacity
Functional adult scale 100% 98% 99%
Functional measuring tape 94% 89% 92%
On-site CD4 analysis 29% 80% 54%
On-site viral load analysis 4% 2% 3%
Guidelines and training
Has HIV guidelines 96% 98% 97%
Staff received HIV training in last year 16% 37% 26%
Has nurse-led HIV treatment 41% 28% 35%
Patient characteristics
Total number of patients 15,671 7,947 23,618
Percent female 66% 61% 64%
Median age (years) 37 35 36
18–29 21% 29% 24%
30–39 38% 39% 39%
40–49 26% 22% 24%
50+ 15% 10% 13%
Year of initiation
2007 6% 5% 6%
2008 18% 11% 16%
2009 20% 15% 18%
2010 24% 22% 23%
2011 26% 31% 28%
2012 5% 16% 9%
WHO Stage
Stage 1 23% 22% 23%
Stage 2 36% 38% 36%
Stage 3 37% 33% 36%
Stage 4 4% 7% 5%
Median baseline CD4 count 172 180 175
doi:10.1371/journal.pone.0135653.t001
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time (22% in 2012). Kenyan hospitals showed the greatest improvement in CD4 testing rates,
rising from 42% in 2009 to 49% in 2012. In contrast, urban health centers in Uganda experi-
enced declines in CD4 testing during this time, falling from 50% to 35%. Notably, 97% of estab-
lished ART patients had a clinical visit every six months in 2012, yet fewer than 50% of patients
received a CD4 test every six months.
Predictors of baseline testing
Controlling for patient and facility characteristics, a more advanced baseline WHO stage was
associated with lower odds of baseline weight testing in Kenya (odds ratio [OR] = 0.49, 95%
confidence interval [CI] = 0.30–0.80 for WHO stage 4 with respect to WHO stage 1) and lower
odds of baseline CD4 testing in both countries (Kenya: OR = 0.56, 95% CI = 0.35–0.91;
Uganda: OR = 0.53, 95% CI = 0.34–0.82) (Table 2).
Having on-site CD4 analysis capacity was associated with increased odds of baseline CD4
testing in Kenya (OR = 3.28, 95% CI = 1.27–8.50) and Uganda (OR = 2.63, 95% CI = 1.31–
5.28). Compared to patients receiving care at hospitals, patients at urban health centers had
increased odds of receiving a baseline CD4 test in Kenya (OR = 4.50, 95% CI = 01.48–13.68)
and those at rural health centers had reduced odds in Uganda (OR = 0.22, 95% CI = 0.10–
0.46). Kenyan patients at facilities with staff who received HIV training in the past year had an
increased odds of a baseline CD4 test (OR = 4.10, 95% CI = 1.50–11.26); by contrast, receipt of
HIV-specific training in Uganda was associated with a lower odds (OR = 0.55, 95% CI = 0.32–
0.93). Ugandan patients at nurse-led programs had an increased odds for the receipt of baseline
CD4 testing (OR = 2.47, 95% CI = 1.34–4.54).
Fig 1. Percent of patients receiving baseline measurements by initiation year, 2007–2012.
doi:10.1371/journal.pone.0135653.g001
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Predictors of established patients receiving recommended
measurements during follow-up
In comparison with patients receiving ART at hospitals, Ugandan patients at urban health cen-
ters had an increased odds of meeting weight guidelines (OR = 3.42, 95% CI = 1.65–7.08) and
those at rural health centers had a reduced odds of meeting CD4 guidelines (OR = 0.21, 95%
CI = 0.08–0.53). Patients at urban health centers had increased odds of meeting CD4 testing
guidelines in Kenya (OR = 2.15, 95% CI = 1.13–4.09).
Kenyan patients had an increased odds of receiving a CD4 test in the past six months if they
received care at a facility with staff who received HIV-specific training during the last year
(OR = 2.74, 95% CI = 1.50–5.02). In Uganda, such training was associated with an increased
odds for patients meeting weight guidelines (OR = 1.74, CI = 1.05–2.89), but a reduced odds
for meeting CD4 testing guidelines (OR = 0.49, 95% CI = 0.24–0.98). In Uganda, patients who
received care at a HIV program with nurse-led care also had increased odds of meeting CD4
testing guidelines (OR = 2.49, 95% CI = 1.17–5.30).
For established patients in Uganda, prior indications of immunological failure were
associated with an increased odds of meeting weight monitoring guidelines (OR = 2.60, 95%
Fig 2. Percent of established patients meeting weight monitoring guidelines, 2009–2012.
doi:10.1371/journal.pone.0135653.g002
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CI = 1.27–5.29), while a previous indication of clinical failure was associated with an increased
odds of meeting the semi-annual CD4 testing guidelines (OR = 1.34, 95% CI = 1.00–1.80)
(Table 3).
Discussion
Kenya and Uganda have both made tremendous gains in enrolling patients on ART. However,
in the setting of increased financial constraints and attention towards quality of care, a careful
examination of monitoring practices is essential. As monitoring guidelines for ART patients
transition to include viral load testing, our findings raise relevant questions about clinic visit
frequency, laboratory capacity, and adherence to international and national norms.
We found that patients were visiting the clinic quite frequently, and on average 90% of
established patients had a visit every three months in 2012. Since most of these patients were
likely to be stable and required little or no intervention, it is important to consider whether
quarterly clinic visits for this established stable population on ART is necessary, as a reduction
in visit frequency could have a significant impact on facility costs and efficiency [31]. Reducing
ART visit frequency could also lessen the burden on patients, as exit interviews conducted as
Fig 3. Percent of established patients meeting CD4monitoring guidelines, 2009–2012.
doi:10.1371/journal.pone.0135653.g003
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Table 2. Predictors of receiving baseline measurements: mixed effects logistic regression results for patients initiating in 2011–12.
Weight at baseline Kenya Uganda
n 4,806 3,002
Patient characteristics
Female 1.08 [0.91,1.28] 1.57* [1.03,2.39]
Age at initiation 1.00 [1.00,1.01] 1.01 [0.99,1.03]
Initiation year 1.59** [1.17,2.16] 0.51* [0.30,0.88]
Facility characteristics
Facility type (ref: Hospital)
Urban health center 1.86 [0.73,4.71] 1.82 [0.50,6.71]
Rural health center 0.73 [0.33,1.61] 0.85 [0.25,2.98]
Government or NGO-owned 1.21 [0.36,4.08] 0.43 [0.16,1.16]
Staff HIV training in last year 1.12 [0.49,2.56] 0.83 [0.33,2.05]
Has nurse-led HIV treatment 1.04 [0.56,1.92] 2.06 [0.70,6.00]
Age of ART program 1.04 [0.87,1.26] 1.01 [0.80,1.28]
Has on-site CD4 analysis 1.31 [0.59,2.86] 1.36 [0.41,4.48]
Clinical characteristics
WHO stage (ref: 1)
Stage 2 0.79* [0.62,0.99] 0.88 [0.47,1.65]
Stage 3 0.51*** [0.41,0.64] 0.95 [0.48,1.87]
Stage 4 0.49** [0.30,0.80] 0.59 [0.22,1.56]
Not recorded 0.63* [0.44,0.90] 0.09*** [0.05,0.17]
CD4 at baseline
n 4,806 3,002
Patient characteristics
Female 0.98 [0.83,1.15] 1.14 [0.93,1.40]
Age at initiation 1.01** [1.00,1.02] 1.01 [1.00,1.02]
Initiation year 1.45* [1.07,1.97] 1.28 [0.96,1.71]
Facility characteristics
Facility type (ref: Hospital)
Urban health center 4.50** [1.48,13.68] 0.57 [0.27,1.20]
Rural health center 0.42 [0.16,1.08] 0.22*** [0.10,0.46]
Government or NGO-owned 1.93 [0.44,8.47] 0.77 [0.43,1.36]
Staff HIV training in last year 4.10** [1.50,11.26] 0.55* [0.32,0.93]
Has nurse-led HIV treatment 0.78 [0.37,1.64] 2.47** [1.34,4.54]
Age of ART program 0.89 [0.72,1.12] 0.92 [0.79,1.07]
Has on-site CD4 analysis 3.28* [1.27,8.50] 2.63** [1.31,5.28]
Clinical characteristics
WHO stage (ref: 1)
Stage 2 0.87 [0.70,1.08] 1.10 [0.83,1.45]
Stage 3 0.44*** [0.35,0.54] 0.71* [0.53,0.95]
Stage 4 0.56* [0.35,0.91] 0.53** [0.34,0.82]
Not recorded 0.13*** [0.09,0.18] 0.23*** [0.16,0.34]
*p < 0.05
**p < 0.01
*** p < 0.001
doi:10.1371/journal.pone.0135653.t002
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part of the larger ABCE project found that patients waited and traveled longer for ART services
than other types of care [28,29]. A recent analysis from Kenya demonstrated the cost-effective-
ness of a model that shifts care from health facilities to the community, thereby reducing the
frequency of ART visits [32]. Another study showed that among virally suppressed patients,
there was no difference in the probability of continued suppression among patients who
returned for care at different frequencies (i.e., three, four, or six months later) [33]. Further
Table 3. Predictors of meeting CD4 and weight monitoring guidelines: mixed effects logistic regression results for established patients in care at
the time of the survey.
Weight at time of survey Kenya Uganda
n 5162 3867
Patient characteristics
Female 1.05 [0.87,1.27] 1.07 [0.89,1.28]
Age at time of survey 1.01** [1.00,1.02] 1.00 [0.99,1.01]
Years on ART 1.15*** [1.07,1.24] 0.94 [0.87,1.02]
Facility characteristics
Facility type (ref: Hospital)
Urban health center 1.16 [0.44,3.03] 3.42*** [1.65,7.08]
Rural health center 0.60 [0.26,1.41] 0.73 [0.37,1.42]
Government/NGO owned 1.14 [0.32,3.97] 0.83 [0.49,1.41]
Staff HIV training in last year 1.57 [0.67,3.70] 1.74* [1.05,2.89]
Has nurse-led HIV treatment 0.71 [0.37,1.35] 1.03 [0.58,1.81]
Age of ART program 1.00 [0.83,1.21] 1.01 [0.88,1.15]
Has on-site CD4 analysis 0.68 [0.30,1.54] 0.69 [0.36,1.32]
Indications of failure in prior 6 months
Immunological criteria 0.90 [0.65,1.26] 2.60** [1.27,5.29]
Clinical criteria 0.77 [0.57,1.04] 1.28 [0.90,1.83]
CD4 at time of survey
n 5,162 3,867
Patient characteristics
Female 1.14* [1.00,1.30] 1.15 [0.97,1.36]
Age at time of survey 1.01* [1.00,1.01] 1.01* [1.00,1.02]
Years on ART 1.04 [0.99,1.10] 0.93 [0.87,1.00]
Facility characteristics
Facility type (ref: Hospital)
Urban health center 2.15* [1.13,4.09] 0.86 [0.35,2.13]
Rural health center 0.74 [0.40,1.36] 0.21** [0.08,0.53]
Government/NGO owned 1.23 [0.51,2.96] 0.93 [0.46,1.90]
Staff HIV training in last year 2.42** [1.35,4.33] 0.49* [0.24,0.98]
Has nurse-led HIV treatment 0.78 [0.49,1.22] 2.49* [1.17,5.30]
Age of ART program 0.92 [0.80,1.05] 1.06 [0.88,1.26]
Has on-site CD4 analysis 1.86* [1.05,3.31] 1.30 [0.54,3.14]
Indications of failure in prior 6 months
Immunological criteria 1.00 [0.79,1.27] 1.25 [0.83,1.87]
Clinical criteria 0.93 [0.74,1.17] 1.34* [1.00,1.80]
*p < 0.05
**p < 0.01
*** p < 0.001
doi:10.1371/journal.pone.0135653.t003
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research is needed to establish whether refining the frequency of clinic visits yields similar
results across ART program settings.
Our study found that most ART patients in our sample regularly visited facilities, suggesting
that patient monitoring may be primarily limited by facility resources and actions rather than
care-seeking behaviours. While low-tech, point-of-care weight monitoring was feasible and
performed according to guidelines at most facilities, less than 50% of patients in care received a
CD4 test during the previous six months in both Kenya and Uganda. Given that ART patient
volumes dramatically increased during the study period, the overall number of CD4 tests has
undoubtedly grown; at the same time, facilities barely kept pace or fell behind in the proportion
of their patients receiving CD4 tests for continuous monitoring. In Uganda, we found that
facilities where staff HIV training was performed within the prior year the odds of having a
CD4 at baseline or afterwards was lower than in facilities where there was no such training.
This could potentially be explained by an even more dramatic increase in patient volumes in
facilities with additional training/expertise leading to demand for testing outstripping testing
capacity. Alternatively, facilities where HIV training was performed may have noted less bene-
fit in recurrent CD4 counts, and reserved testing for patients who appeared clinically ill or had
another indication for CD4 testing. We also found that CD4 testing was strongly related to
having on-site analysis capacity. As CD4 testing remains one of the primary means for deter-
mining ART initiation, our results support equipping facilities to analyze CD4 tests, or at a
minimum improving systems through which off-site CD4 test analysis can occur efficiently
and at low cost. Our findings complement previous research on the benefits of point-of-care
CD4 testing to reduce attrition between testing and initiation [34,35].
Experiences with off-site CD4 analysis are also highly relevant as countries begin scaling up
viral load monitoring. While viral load testing offers benefits over immunological and clinical
monitoring [8], this guideline shift does not expressly address the underlying issue of access to
monitoring. For instance, Uganda plans to use its existing sample transport referral network to
deliver and analyze viral load samples at a centralized location in Kampala; while this approach
may help with the initial roll-out of viral load testing, it does not improve point-of-care needs
and may remain limited by the same infrastructure challenges underlying CD4 testing [36].
New guidelines call for immunological testing in instances where viral load is unavailable
[8,20], but our findings demonstrate that such alternatives (i.e., CD4 testing) may remain inac-
cessible for many patients, particularly in rural areas. Greater policy attention is needed to
address these limitations to laboratory capacity in sub-Saharan Africa, especially as the need
for more ART services in rural areas is likely to grow. To this end, the development of effective
point-of-care viral load testing could be an important innovation [37].
Our findings should be viewed in light of a number of limitations. First, we only examined
tests and visits recorded in patient charts. While these data reflect the information available to
providers for monitoring purposes, we cannot quantify how much record-keeping practices
affected our results concerning gaps between recommended and observed testing practices.
Second, patient charts did not contain demographic characteristics, such as educational levels
and household wealth, which could be important determinants of health behaviors. Third,
chart storage for deceased or defaulted patients may vary across facilities, a practice that could
introduce biases. Further, electronic medical records received from six facilities may differ
from the paper records used at the remaining facilities. At the two Ugandan facilities with elec-
tronic records, 100% of patients received a CD4 test at initiation. Since we sampled only a few
facilities with electronic records, we are unable to determine if this relationship was due to
record-keeping procedures, overall managerial and financial capacity, or a causal relationship
between electronic records and better monitoring.
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Despite these limitations, our study identifies a clear gap between prior immunological
monitoring guidelines and clinical practice. These findings are particularly relevant as the
number of patients eligible for ART continues to increase due to changing initiation guide-
lines.5 Future research will need to address the frequency of routine clinic visits and testing,
while national HIV treatment programs will also need to look toward improving current labo-
ratory capacity. Striking this balance in terms of patient visit quantity and quality is critical to
ensuring that patients receive the maximum benefits of ART.
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